Company news: AstraZeneca, Roche

Share this article:
In a drive to preserve its Crestor market share, AstraZeneca said it is picking up the difference between the cost of the generic and its branded statin in Canada, where Mylan got the okay for a copycat launch in March. Although AZ rolled out a co-pay card in February, the effort garnered fresh attention today with Ontario's announcement that the generic and brand are interchangeable on that province's market. Canadian provinces individually determine formulary parity. The cards are supplied and processed by STI Technologies, which told MM&M that Ontario is its biggest prescription market.

In a sign that the deepening EU financial crisis is putting stress on hospital dispensaries, Roche is now demanding hospitals in Spain and Portugal pay down their debts if they want to receive more medications, reported Bloomberg. This latest move by the Swiss drugmaker is part of the larger debt crisis narrative. Several locations were already on the pay-to-play list as of last year, but the latest change is that the number of hospitals on this list has continued to grow. Roche now requires several Greek hospitals to pay for drugs before delivery, according to Bloomberg.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.